Literature DB >> 11026448

Innate production of interleukin-10 and tumor necrosis factor affects the risk of multiple sclerosis.

B A de Jong1, H M Schrijver, T W Huizinga, E L Bollen, C H Polman, B M Uitdehaag, M C Kersbergen, A Sturk, R G Westendorp.   

Abstract

Multiple sclerosis (MS) typically presents with a relapsing-remitting onset. This can be distinguished from primary progressive MS. Typical MS is characterized by a profound inflammatory reaction in which anti-inflammatory cytokine interleukin-10 (IL-10) and pro-inflammatory cytokine tumor necrosis factor (TNF) may play a pivotal role. We tested the hypothesis that patients with MS have a distinct innate cytokine production that contributes to the susceptibility for and outcome of MS. The innate cytokine production of patients was estimated as the average production of cytokines in lipopolysaccharide -stimulated whole-blood cultures of 2 to 5 first-degree healthy family members. A total of 126 family members of 50 patients with typical MS, 61 family members of 25 patients with primary progressive MS, and 129 control subjects of 54 families were enrolled in this study. We found that members of families with low IL-10 and high TNF production had a fourfold increased risk of developing typical MS compared with members of families with high IL-10 and low TNF production. Patients with MS were eightfold more likely to develop typical MS than primary progressive MS when they belonged to families with low IL-10 and high TNF production. The presence of human leukocyte antigen-DR2 was associated with MS but not with TNF production. This study shows that typical MS is associated with an innate pro-inflammatory cytokine profile in contrast to primary progressive MS.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11026448     DOI: 10.1002/1531-8249(200010)48:4<641::aid-ana11>3.3.co;2-q

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  8 in total

1.  A genome-wide linkage scan reveals CD53 as an important regulator of innate TNF-alpha levels.

Authors:  Steffan D Bos; Nico Lakenberg; Ruud van der Breggen; Jeanine J Houwing-Duistermaat; Margreet Kloppenburg; Anton J M de Craen; Marian Beekman; Ingrid Meulenbelt; P Eline Slagboom
Journal:  Eur J Hum Genet       Date:  2010-04-21       Impact factor: 4.246

Review 2.  Gender issues and multiple sclerosis.

Authors:  Rhonda R Voskuhl
Journal:  Curr Neurol Neurosci Rep       Date:  2002-05       Impact factor: 5.081

Review 3.  Preclinical Autoimmune Disease: a Comparison of Rheumatoid Arthritis, Systemic Lupus Erythematosus, Multiple Sclerosis and Type 1 Diabetes.

Authors:  Giulia Frazzei; Ronald F van Vollenhoven; Brigit A de Jong; Sarah E Siegelaar; Dirkjan van Schaardenburg
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

4.  IL-10 Gene Polymorphisms and IL-10 Serum Levels in Patients with Multiple Sclerosis in Lithuania.

Authors:  Ugne Masilionyte; Greta Gedvilaite; Kriste Kaikaryte; Alvita Vilkeviciute; Loresa Kriauciuniene; Brigita Glebauskiene; Renata Balnyte; Rasa Liutkeviciene
Journal:  Brain Sci       Date:  2022-06-18

5.  Losartan Mitigates Oxidative Stress in the Brains of Aged and Inflamed IL-10-/- Mice.

Authors:  Nazaneen Saleh; Caglar Cosarderelioglu; Ramya Vajapey; Jeremy Walston; Peter M Abadir
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2022-09-01       Impact factor: 6.591

6.  Cognitive deficits in interleukin-10-deficient mice after peripheral injection of lipopolysaccharide.

Authors:  Amy F Richwine; Nathan L Sparkman; Ryan N Dilger; Jessica B Buchanan; Rodney W Johnson
Journal:  Brain Behav Immun       Date:  2009-03-09       Impact factor: 7.217

7.  T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis.

Authors:  Chris J Hedegaard; Martin Krakauer; Klaus Bendtzen; Henrik Lund; Finn Sellebjerg; Claus H Nielsen
Journal:  Immunology       Date:  2008-04-04       Impact factor: 7.397

Review 8.  Vitamin D Actions on CD4(+) T Cells in Autoimmune Disease.

Authors:  Colleen Elizabeth Hayes; Shane L Hubler; Jerott R Moore; Lauren E Barta; Corinne E Praska; Faye E Nashold
Journal:  Front Immunol       Date:  2015-03-18       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.